St. Jude Children's Research Hospital - Recruiting N/A to 21 years. - Molecular and Histopathologic Characterization of Atypical Teratoid Rhabdoid Tumors, Choroid Plexus Carcinomas, Ependymomas and Medulloblastoma/PNET of the Pediatric CNS.
Sidney Kimmel Comprehensive Cancer Center - Recruiting 18 years or older. - A Phase I Open Label Safety Study to Evaluate the Pharmacokinetic Profile and Tolerance of Mibefradil Dose Finding in Subjects With Recurrent High-Grade Glioma Undergoing Standard, Repeated Temozolomide Treatment.
mibefradil dihydrochloride; temozolomide; 3'-deoxy-3'-[18F]fluorothymidine; pharmacological study
DEKK-TEC, Inc. - Recruiting 18 years or older. - A Phase II Trial: Safety and Tolerance of Intravenous 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Malignancies Involving the Central Nervous System.
National Cancer Institute (NCI) - Recruiting 18 years or older. - A Phase II Pilot Trial of Radiation Therapy With Concurrent and Adjuvant Temozolomide, Tamoxifen and Carboplatin (T2C) in the Treatment of Patients With Primary Central Nervous System Malignant Gliomas.
Cancer Research UK - Recruiting 18 years to 70 years. - A Cancer Research UK Phase I Trial of Olaparib (AZD2281), an Oral PARP Inhibitor, in Combination With Extended Low-Dose Oral Temozolomide in Patients With Relapsed Glioblastoma.
olaparib; temozolomide; gene expression analysis; protein expression analysis; laboratory biomarker analysis; pharmacological study; diffusion-weighted magnetic resonance imaging; dynamic contrast-enhanced magnetic resonance imaging; therapeutic conventional surgery
OHSU Knight Cancer Institute - Recruiting 18 years to 75 years. - A Phase I/II Study of Patient With Newly Diagnosed Primary Central Nervous System Lymphoma Treated With Methotrexate/BBBD, and Adding Rituximab (an Anti CD-20 Antibody) and Carboplatin, to the Treatment Regimen.
The Methodist Hospital System - Recruiting 18 years to 79 years. - Phase II Trial of Chemotherapy With Temozolomide in Combination With Topotecan for Central Nervous System (CNS) Metastasis of Solid Tumors.
National Cancer Institute (NCI) - Recruiting 18 years or older. - Phase I/Randomized Phase II Trial of Either Dasatinib or Placebo Combined With Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (GBM).
National Cancer Institute (NCI) - Recruiting 1 year to 21 years. - A Phase I/II Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-Met, in Children With Relapsed/Refractory Solid Tumors, Primary CNS Tumors, and Anaplastic Large Cell Lymphoma.
crizotinib; pharmacogenomic studies; pharmacological study
National Cancer Institute (NCI) - Recruiting 3 years to 30 years. - Study Of Reduced Dose Craniospinal Radiotherapy (1800 cGy) And Chemotherapy In Children With Newly-Diagnosed Standard-Risk Posterior Fossa Primitive Neuro-ectodermal Tumor (PNET/Medulloblastoma).
National Cancer Institute (NCI) - Recruiting 18 years or older. - Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial..